Here’s What Competition Looks Like In India’s Humira Biosimilars Market
Competition may be just readying to jump in and gnaw into Humira’s share in Europe later this year, but the Indian market for biosimilar adalimumab already has more than half a dozen players, with distinct pricing characteristics. Scrip takes a peek into the competitive market.
You may also be interested in...
Allergan brings with it a market-leading ophthalmology franchise and promising prospects for Botox in India, opening up new avenues for growth for AbbVie, which so far has been measured compared with some multinational peers in the country.
Led by eight-week, pan-genotypic combo Mavyret, AbbVie’s HCV franchise grows despite a declining US market that has taken a toll on competitors Gilead and Merck. Still, AbbVie expects a falloff in the third quarter.
A recent panel discussion in India brought to the fore simmering tensions over the country's guidelines on biosimilars, with some panelists suggesting the guidelines compromise on patient safety while other experts sought to tone down any alarmist conclusions.